SEHK:3696Life Sciences
Insilico Medicine Advances AI Drug Discovery Model With New Partnerships
Insilico Medicine Cayman TopCo (SEHK:3696) has secured a partnership with Qilu Pharmaceutical focused on cardiometabolic disease drug candidates.
The company received FDA IND clearance for a novel NLRP3 inhibitor, ISM8969, targeting Parkinson's Disease.
Insilico launched its Science MMAI Gym to make its AI tools available to pharma R&D partners.
A global co development agreement for ISM8969 was signed with Hygtia Therapeutics, expanding the candidate's reach.
For investors tracking AI...